Overall, the ex vivo culture data showed the safety and an overall inhibitory effect of OVM on several tumor types and further provided evidence for using the combination of MXRA8 and ZAP as a pair of predictive biomarkers in OVM therapy in liver and kidney tumors (Fig. 7). The gene discussed is MXRA8; the disease is kidney neoplasm.